Takeda discontinues the development of Rozerem (ramelteon)the MT1 and MT2 receptor agonist for Insomnia in the EU following the withdrawal...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Quviviq (daridorexant), from Idorsia Pharmaceuticals, intended for the treatment of insomnia. Quviviq will be available as 25 mg and 50 mg film-coated tablets.
Merck Inc. announced that the FDA has on 13 August 2014 approved Belsomra (suvorexant) for adults with Insomnia who have...
Idorsia Ltd announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for daridorexant, Idorsia's investigational dual orexin receptor antagonist, for the treatment of adult patients with insomnia.
Idorsia announced that the FDA has accepted the new drug application (NDA) for review of Idorsia’s investigational dual orexin receptor antagonist, daridorexant, for the treatment of adult patients with insomnia.
Eisai Co., Ltd. announced that the FDA approved the new drug application for its in-house discovered and developed orexin receptor...
Idorsia Ltd announced that Health Canada has granted marketing authorization for Quviviq (daridorexant) for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, on April 28, 2023.
Idorsia Ltd announced the European Commission (EC) has granted marketing authorization for Quviviq (daridorexant) for the treatment of adult patients with insomnia characterized by symptoms present for at least three months and considerable impact on daytime functioning.
Eisai announced that a new drug application has been submitted to the FDA for E 2006 (lemborexant), an investigational agent...